Transcatheter mitral valve replacement — a new option for a selected group of patients?
, 1718
Abstract
Mitral regurgitation (MR) is the second most common valvular disease. Symptomatic MR is associated with a poor prognosis. Cardiac surgery is recommended in the severe form of the disease. If the surgical risk is high or functional mitral regurgitation repair/replacement cannot be combined with aorto-coronary bypass graft surgery, a transcatheter edge-to-edge valve repair should be considered. Currently, there is no recommended procedure in patients with severe symptomatic MR, high cardiac surgical risk, and low probability of success or contraindications to the percutaneous edge-to-edge treatment. A recent alternative is the mitral valve implantation using a transapical approach or through the interatrial septum. Currently, the only CE-marked transcatheter bioprothesis valve using transapical approach and implanted without extracorporeal circulation support is the Tendyne valve. This paper discusses the safety, clinical efficacy and cost effectiveness of this valve and the size of the target population in Poland. The clinical efficacy was evaluated in a study of 100 patients with severe symptomatic MR. The total 2-year mortality was 39%. The hospitalisation rate due to heart failure decreased from 1.3 events/year prior to the surgery to 0.51. MR was not recorded in 93.2% of the survivors. An economic analysis accounting for the survival, health-related quality of life, and the risk of hospitalisation due to heart failure showed that the Tendyne system is cost-effective compared to pharmacological treatment: the incremental cost-utility ratio equalled 93,324–110,696 PLN, depending on the approach, clearly below the official threshold in Poland. The annual number of eligible patients was estimated at 60.
Keywords: mitral regurgitationmitral valve implantationTendynecost-effectiveness
References
- Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the eurobservational research programme valvular heart disease II survey. Circulation. 2019; 140(14): 1156–1169.
- Cahill TJ, Prothero A, Wilson Jo, et al. Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation. Heart. 2021; 107(12): 1003–1009.
- McCarthy KP, Ring L, Rana BS. Anatomy of the mitral valve: understanding the mitral valve complex in mitral regurgitation. Eur J Echocardiogr. 2010; 11(10): i3–i9.
- Nogara A, Minacapelli A, Zambelli G, et al. Functional anatomy and echocardiographic assessment in secondary mitral regurgitation. J Card Surg. 2022; 37(12): 4103–4111.
- Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007; 28(11): 1358–1365.
- Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014; 63(2): 185–186.
- Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013; 14(7): 611–644.
- Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16(7): 777–802.
- Vahanian A, Beyersdorf F, Praz F, et al. 2ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561–632.
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143(5): e35–e71.
- Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379(24): 2307–2318.
- Lim D, Herrmann H, Grayburn P, et al. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. Structural Heart. 2021; 5(3): 227–233.
- Wienemann H, Mauri V, Ochs L, et al. Contemporary treatment of mitral valve disease with transcatheter mitral valve implantation. Clin Res Cardiol. 2023; 112(5): 571–584.
- Dahle G. Current devices in TMVI and their limitations: focus on tendyne. Front Cardiovasc Med. 2020; 7: 592909.
- Muller D, Farivar R, Jansz P, et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol. 2017; 69(4): 381–391.
- Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol. 2019; 73(11): 1250–1260.
- Muller DWM, Sorajja P, Duncan A, et al. 2-Year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021; 78(19): 1847–1859.
- Wilde N, Tanaka T, Vij V, et al. Characteristics and outcomes of patients undergoing transcatheter mitral valve replacement with the Tendyne system. Clin Res Cardiol. 2024; 113(1): 1–10.
- Gössl M, Thourani V, Babaliaros V, et al. Early outcomes of transcatheter mitral valve replacement with the Tendyne system in severe mitral annular calcification. EuroIntervention. 2022; 17(18): 1523–1531.
- Witkowski A, Dudek D, Bartuś S, et al. Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland. Cardiol J. 2022; 29(3): 369–380.
- Goates S, Baron SJ, Arnold SV, et al. PCV30 Estimating health-state utility in patients with heart failure: mapping the Kansas City cardiomyopathy questionnaire to SF-6D utility scores. Value Health. 2019; 22: S124.
